Biblio Discovery — Demo Discovery Service

5 hasil untuk "Chi Lin"

Menampilkan 1–5 · 0,39 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

    Giuseppe Curigliano; Hans A. J. Gelderblom; Nicolas Mach dkk.

    Clinical Cancer Research · 2021 · Inggris · OpenAlex Scopus

    Abstract Purpose: Sabatolimab (MBG453) and spartalizumab are mAbs that bind T-cell immunoglobulin domain and mucin domain-3 (TIM-3) and programmed death-1 (PD-1), respectively. This phase I/II study evaluated the safety and efficacy of sabatolimab, with or without spartalizumab, in patients with…

  2. Artikel Jurnal

    Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer

    Kuan‐Wei Huang; Fu‐Fei Hsu; Jiantai Timothy Qiu dkk.

    Science Advances · 2020 · Inggris · OpenAlex Scopus

    T cells, augmented the efficacy of cancer vaccine immunotherapy, and suppressed HCC progression. Our work presents nanotechnology-enabled dual delivery of siRNA and plasmid DNA that selectively targets and reprograms the immunosuppressive tumor microenvironment to improve cancer immunotherapy.

  3. Artikel Jurnal Teks lengkap

    PD-1 Blockade in Anaplastic Thyroid Carcinoma

    Jaume Capdevila; Lori J. Wirth; Thomas Ernst dkk.

    Journal of Clinical Oncology · 2020 · Inggris · OpenAlex Scopus

    PURPOSE Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options for patients with BRAF-wild type disease. As part of a phase I/II study in patients with advanced/metastatic solid tumors, patients with anaplastic thyroid…

  4. Artikel Jurnal Teks lengkap

    Plasma proteomic associations with genetics and health in the UK Biobank

    Benjamin B. Sun; Joshua Chiou; Matthew Traylor dkk.

    Nature · 2023 · Inggris · OpenAlex Scopus

    Abstract The Pharma Proteomics Project is a precompetitive biopharmaceutical consortium characterizing the plasma proteomic profiles of 54,219 UK Biobank participants. Here we provide a detailed summary of this initiative, including technical and biological validations, insights into proteomic…